CD8A and neoplasm: Our data demonstrated that the human CD8+ T cells with activation of DC/tumor fusion vaccine+LPS-Nb36 persisted for more than 4 weeks and were longer in tumor-bearing mice than in other groups of T cells, whether these cells were in the peripheral blood, spleen, or within the tumor itself.